These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10851028)

  • 1. Role of matrix metalloproteinases in development of diabetic nephropathy.
    Khasigov PZ; Ktzoeva SA; Gatagonova TM; Tareeva IE; Grachev SV; Berezov TT
    Biochemistry (Mosc); 2000 May; 65(5):519-24. PubMed ID: 10851028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
    Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
    Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
    McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
    Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions.
    Zaoui P; Cantin JF; Alimardani-Bessette M; Monier F; Halimi S; Morel F; Cordonnier D
    Diabetes Metab; 2000 Jul; 26 Suppl 4():25-9. PubMed ID: 10922970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion.
    Tomita M; Koike H; Han GD; Shimizu F; Kawachi H
    Clin Exp Nephrol; 2004 Mar; 8(1):17-26. PubMed ID: 15067512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
    Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal transplant fibrosis correlates with intragraft expression of tissue inhibitor of metalloproteinase messenger RNA.
    Nicholson ML; Waller JR; Bicknell GR
    Br J Surg; 2002 Jul; 89(7):933-7. PubMed ID: 12081746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
    Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
    Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvascular basement membranes in diabetes mellitus.
    Tsilibary EC
    J Pathol; 2003 Jul; 200(4):537-46. PubMed ID: 12845621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin II receptor blocker on glucose-induced mRNA expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat mesangial cells.
    Ding HL; Guo Y; Xu MT; Li HY; Fu ZZ
    Chin Med J (Engl); 2007 Nov; 120(21):1886-9. PubMed ID: 18067760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost.
    Oh DJ; Martin JL; Williams AJ; Peck RE; Pokorny C; Russell P; Birk DE; Rhee DJ
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):953-63. PubMed ID: 16505029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Porphyromonas gingivalis affects host collagen degradation by affecting expression, activation, and inhibition of matrix metalloproteinases.
    Zhou J; Windsor LJ
    J Periodontal Res; 2006 Feb; 41(1):47-54. PubMed ID: 16409255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients.
    Lobmann R; Ambrosch A; Schultz G; Waldmann K; Schiweck S; Lehnert H
    Diabetologia; 2002 Jul; 45(7):1011-6. PubMed ID: 12136400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue.
    Lichtinghagen R; Musholt PB; Stephan C; Lein M; Kristiansen G; Hauptmann S; Rudolph B; Schnorr D; Loening SA; Jung K
    Anticancer Res; 2003; 23(3B):2617-24. PubMed ID: 12894549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease.
    Rosemar A; Ivarsson ML; Börjesson L; Holmdahl L
    Scand J Gastroenterol; 2007 Feb; 42(2):215-20. PubMed ID: 17327941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.
    Bjerkeli V; Halvorsen B; Damås JK; Nordøy I; Yndestad A; Aukrust P; Frøland SS
    Ann Rheum Dis; 2004 Dec; 63(12):1659-63. PubMed ID: 15547092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.